Demographics and clinical characteristics
| Patient characteristics . | n = 36 . |
|---|---|
| Age, median (range) | 65 (19-83) |
| Age <65 y, n (%) | 16 (44) |
| Disease, n (%) | |
| DLBCL | 20 (56) |
| Other NHL | 9 (25) |
| Other | 7 (19) |
| CD19 CAR T-cell product, n (%) | |
| Tisa-cel | 10 (28) |
| Axi-cel | 10 (28) |
| Other | 16 (44) |
| Status of disease, n (%) | |
| Remission | 31 (86) |
| Refractory | 5 (14) |
| Postinfusion complications and related treatments, n (%) | |
| CRS | 27 (75) |
| ICANS | 13 (36) |
| Corticosteroids | 14 (39) |
| anti-IL-6R | 27 (75) |
| Vaccination type, n (%) | |
| BNT162b2 (Pfizer-BioNTech) | 23 (64) |
| mRNA-1273 (Moderna) | 4 (11) |
| Vakzevria (AstraZeneca) | 4 (11) |
| Vakzevria/BNT162b2 | 5 (14) |
| Circulating B cells at vaccination, n (%) | 17 (46) |
| Days from CAR T-cell therapy to vaccination (n = 15), median (range) | 257 (115-817) |
| Days from vaccination to CAR T-cell therapy (n = 21), median (range) | 208 (70-365) |
| Patient characteristics . | n = 36 . |
|---|---|
| Age, median (range) | 65 (19-83) |
| Age <65 y, n (%) | 16 (44) |
| Disease, n (%) | |
| DLBCL | 20 (56) |
| Other NHL | 9 (25) |
| Other | 7 (19) |
| CD19 CAR T-cell product, n (%) | |
| Tisa-cel | 10 (28) |
| Axi-cel | 10 (28) |
| Other | 16 (44) |
| Status of disease, n (%) | |
| Remission | 31 (86) |
| Refractory | 5 (14) |
| Postinfusion complications and related treatments, n (%) | |
| CRS | 27 (75) |
| ICANS | 13 (36) |
| Corticosteroids | 14 (39) |
| anti-IL-6R | 27 (75) |
| Vaccination type, n (%) | |
| BNT162b2 (Pfizer-BioNTech) | 23 (64) |
| mRNA-1273 (Moderna) | 4 (11) |
| Vakzevria (AstraZeneca) | 4 (11) |
| Vakzevria/BNT162b2 | 5 (14) |
| Circulating B cells at vaccination, n (%) | 17 (46) |
| Days from CAR T-cell therapy to vaccination (n = 15), median (range) | 257 (115-817) |
| Days from vaccination to CAR T-cell therapy (n = 21), median (range) | 208 (70-365) |
anti-IL-6R, anti–interleukin 6 receptor (tocilizumab); Axi-cel, axicabtagene ciloleucel; CRS, cytokine release syndrome; DLBCL, diffuse large B-cell lymphoma; ICANS, immune effector cell–associated neurotoxicity syndrome; mRNA, messenger RNA; NHL, non-Hodgkin lymphoma; Tisa-cel, tisagenlecleucel.